As most studies focused on sporadic rather than familial breast cancer cases, and employed screening methods preferentially capable of detecting protein-truncating mutations (Ángele and Hall, 2000), there might be more ATM non-truncating mutations and/or polymorphisms or variants (e.g. missense mutations) that affect breast cancer risk. The gene discussed is ATM; the disease is breast carcinoma.